FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to NICE.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pulmonary Embolism · Interventional Procedure
- Sub-indication
- General
Related signal: Registry Launched to Evaluate Thrombectomy for Pulmonary Embolism